Shares of Prana Biotechnology Ltd. (NASDAQ:PRAN) saw unusually-strong trading volume on Tuesday . Approximately 397,458 shares traded hands during mid-day trading, an increase of 66% from the previous session’s volume of 239,764 shares.The stock last traded at $5.66 and had previously closed at $5.80.

Separately, Zacks Investment Research upgraded Prana Biotechnology from a “sell” rating to a “hold” rating in a research report on Wednesday, August 3rd.

The stock’s market capitalization is $8.13 million. The company’s 50-day moving average is $4.73 and its 200-day moving average is $3.83.

Prana Biotechnology Limited (Prana) is an Australia-based development stage medical biotechnology Company. The Company is engaged in commercializing research into Alzheimer’s disease, Huntington disease and other major age-related degenerative disorders. The Company’s lead drug candidate, PBT2 is being developed for the treatment of Alzheimer’s and Huntington’s diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.